

**RADIOBIOLOGICAL MODELLING OF GOLD
NANOPARTICLES RADIOSENSITIZATION
EFFECTS IN CONVENTIONAL AND ADVANCED
RADIOTHERAPY TECHNIQUES**

RAIZULNASUHA BINTI AB RASHID

UNIVERSITI SAINS MALAYSIA

2021

**RADIOBIOLOGICAL MODELLING OF GOLD
NANOPARTICLES RADIOSENSITIZATION
EFFECTS IN CONVENTIONAL AND ADVANCED
RADIOTHERAPY TECHNIQUES**

by

RAIZULNASUHA BINTI AB RASHID

**Thesis submitted in fulfilment of the requirements for the degree of
Doctor of Philosophy**

June 2021

ACKNOWLEDGEMENT

In the name of Allah swt the Most Gracious and the Most Merciful Alhamdulillah, Praise to Allah for His endless blessings and strengths for me to complete this thesis. First and foremost, I would like to express my deepest gratitude to my supervisor, Dr. Wan Nordiana Wan Abd Rahman, for her invaluable guidance during my candidature. Many thanks to my co-supervisor Profesor Dr. Khairunisak Abdul Razak and Dr Mohd Hafiz Bin Mohd Zin for their support during the course of my study. Special appreciations to all the staffs at the Department of Nuclear Medicine, Radiotherapy and Oncology at the Hospital Universiti Sains Malaysia, especially to Mdm. Norhayati Dollah and Mr Reduan Abdullah for being such a great mentor during my data collection process. Deepest gratitude to Prof Moshi Geso for beamtime arrangement at Australian Synchrotron. Special thanks also to Dr Andrew Stevenson from Imaging and Medical Beamline and Dr. Stephanie Corde from Prince of Wales Hospital with their assistance during data collection at Australian Synchrotron. My proton beam irradiation would not be possible without the help from Prof Ryohei Sasaki and Dr Hiroaki Akasaka from Kobe University Hospital, Dr. Takahiro Tominaga from Hiroshima International University and staffs from Hyogo Ion Beam Medical Centre. The research also indebted to Malaysian Ministry of Higher Education for their financial support through FRGS grant (No:203/PPSK/6171160). To my postgraduate colleagues: Belle, Emi, Hamizah, Afiq, Nashrul and Fazi, thanks for all the positive experiences. Special gratitude to my family especially my beloved mother, Zainab Hamat for the endless support, encouragement and countless love for me especially during the challenging time of my doctorate study. Thank you.

TABLE OF CONTENTS

ACKNOWLEDGEMENT	ii
TABLE OF CONTENTS.....	iii
LIST OF TABLES	xiii
LIST OF FIGURES	xxi
LIST OF ABBREVIATIONS	xxxii
LIST OF SYMBOLS	xxxiv
ABSTRAK	xxxvi
ABSTRACT	xxxviii
CHAPTER 1 INTRODUCTION	1
1.1 Modern radiotherapy in cancer treatment.....	1
1.2 Radiobiology in radiotherapy	3
1.2.1 Radiation induced cellular damage	4
1.2.1(a) The time scale of radiation effects	4
1.2.1(a)(i) Physical phase	4
1.2.1(a)(ii) Chemical phase	4
1.2.1(a)(iii) Biological Phase.....	5
1.2.1(b) DNA damage mechanism	6
1.2.2 Radiation cell survival and damage.....	8
1.2.2(a) Cell survival curves.....	8
1.3 Radiobiological model.....	9
1.3.1 Application of the LQ model.....	9
1.3.1(a) The validity of the LQ model.....	11

1.4	Problem statement and rationale of the study	12
1.5	General objective	13
1.6	Specific objectives	13
1.7	Thesis outlines	14
CHAPTER 2 LITERATURE REVIEW		17
2.1	Nanomedicine in radiotherapy	17
2.2	Application of Gold Nanoparticles (AuNPs) in radiotherapy	20
2.2.1	Characteristic and properties of AuNPs	21
2.2.2	Radiosensitization Effects by AuNPs.....	23
2.2.2(a)	Theoretical dose enhancement by high Z materials..	23
2.2.3	Quantification of Radiosensitization Effects by AuNPs	25
2.2.3(a)	<i>In-vitro</i>	25
2.2.3(b)	<i>In-vivo</i>	26
2.2.3(c)	Monte Carlo	27
2.3	Mechanisms of AuNPs radiosensitization.....	28
2.4	Pre-clinical application of AuNPs as a radiosensitizer in radiotherapy ..	31
2.4.1	Superficial and orthovoltage therapy.....	31
2.4.2	Megavoltage photon and electron beam radiotherapy.....	32
2.4.3	Brachytherapy.....	33
2.4.4	Proton and carbon ion beam therapy	33
2.5	Radiobiological model in clinical radiotherapy.....	35
2.5.1	Linear quadratic model.....	35
2.5.2	Multi-target model.....	36
2.5.3	Repairable conditionally repairable model.....	36

2.5.4	Pade' linear quadratic model	37
2.5.5	Repair model	38
2.5.6	Kavanagh-newman model	38
2.5.7	Two components model	39
CHAPTER 3 MATERIALS AND METHODS		40
PART 1: CONVENTIONAL RADIOTHERAPY; PHOTON BEAM, ELECTRON BEAM AND BRACHYTHERAPY		40
3.1	Cell culture maintenance and protocol	42
3.1.1	Cervical cancer cell lines (HeLa cells) preparation.....	42
3.2	Gold Nanoparticles (AuNPs) Preparations	44
3.3	Gold nanoparticles (AuNPs) cellular uptake and localization.....	45
3.3.1	Cellular uptake measurement of AuNPs for HeLa cells.	45
3.3.2	Localization by light microscope observation for HeLa 116 cells.	45
3.4	Cytotoxicity assay for HeLa cells.....	46
3.4.1	Presto blue assay.....	46
3.5	Cell survival study	47
3.5.1	Irradiation with external beam radiotherapy (photon and electron beams).....	47
3.5.1(a)	Cells samples preparation	47
3.5.1(b)	Irradiation Setup.....	47
3.5.1(c)	Radiation Dosimetry for photon and electron beams	49
3.5.2	Irradiation with HDR brachytherapy	50
3.5.2(a)	Cells samples preparation	50
3.5.2(b)	Brachytherapy irradiation setup	50

3.5.2(c)	Radiation dosimetry for brachytherapy	51
3.6	Cell survival measurements.....	51
3.6.1	Clonogenic assay	51
3.7	Result Analysis	53
3.7.1	Radiobiological modelling	53
3.7.2	Methodologies for quantifying radiobiological enhancement impact of AuNPs.	54
3.7.2(a)	Sensitisation Enhancement Ratio (SER) calculation	54
3.7.2(b)	Radiation Enhancement Factor (REF) calculation ...	55
3.7.2(c)	Radiation Enhancement Ratio (RER) calculation.....	56
3.7.2(d)	Dose Enhancement Factor (DEF _{xGy}) calculation	58
3.8	Statistical analysis.....	59
CHAPTER 4 RESULTS		60
4.1	Gold nanoparticles (AuNPs) cellular uptake into HeLa cells.....	60
4.2	AuNPs localization inside HeLa cells	62
4.3	Gold nanoparticles (AuNPs) cytotoxicity on HeLa cells	63
4.4	Cell survival analysis using radiobiological models	66
4.4.1	Linear quadratic (LQ) model.....	67
4.4.2	Multi-target (MT) model	73
4.4.3	Repairable conditionally repairable (RCR) model	79
4.4.4	Pade' linear quadratic (PLQ) model.....	85
4.4.5	Two-component (2C) model and Kavanagh & Newman (KN) model	91
4.4.6	Repair model (RM).....	97
4.5	Comparison of cell survival analysis according to beam quality	102

4.5.1	Radiobiological parameters analysis	109
4.6	Quantification of DEF, SER, RER and REF	118
4.6.1	Dose Enhancement Factor (DEF).....	118
4.6.2	Sensitization Enhancement Ratio (SER).....	124
4.6.3	Radiation enhancement ratio (RER).....	131
4.6.4	Radiation enhancement factor (REF)	137
4.7	The influence of AuNPs sizes, concentrations and cell types on the radiosensitization effects.	138
4.7.1	Effect of AuNPs sizes.....	138
4.7.2	Effect of AuNPs concentrations	140
4.7.3	Effect of cell types.....	142
4.8	Radiation dose verification during samples irradiation	143
4.8.1	Megavoltage photon beams.....	143
4.8.2	Megavoltage electron beams	147
4.8.3	Brachytherapy: Isodose distribution.....	150
CHAPTER 5 DISCUSSION.....		152
5.1	Gold Nanoparticles (AuNPs) cellular uptake	153
5.2	AuNPs localization in cells.....	154
5.3	Cytotoxicity of the gold nanoparticles (AuNPs)	156
5.4	Cell survival analysis using radiobiological models	159
5.5	Radiobiological parameters analysis	164
5.6	Quantification of DEF, SER, RER and REF	167
5.7	Effect of AuNPs sizes.....	169
5.8	Effect of AuNPs concentrations	173

5.9	Effect of AuNPs on cell types	174
-----	-------------------------------------	-----

CHAPTER 6 PART II: ADVANCED RADIOTHERAPY; PROTON BEAM THERAPY 176

6.1	Introduction.....	176
6.1.1	Introduction to proton beam therapy	176
6.2	Literature review.....	179
6.3	Materials and Methods	182
6.3.1	Cell samples preparation	182
6.3.2	Cellular uptake measurement of AuNPs for HCT 116 cells. ..	182
6.3.3	AuNPs localisation by light microscopy for HCT 116 cells. ..	183
6.3.4	Cytotoxicity assay for HCT 116 cells.	183
6.3.4(a)	Presto blue assay	183
6.3.5	Proton Beam Irradiation	184
6.3.5(a)	Cell survival measurements	186
6.3.5(b)	Intracellular ROS measurements	186
6.3.5(c)	Radiation dosimetry	187
6.4	Results	188
6.4.1	Gold nanoparticles (AuNPs) cellular uptake into HCT 116 cells.....	188
6.4.2	Gold nanoparticles (AuNPs) localization for HCT 116 cells..	189
6.4.3	AuNPs cytotoxicity test on HCT 116 cells.....	190
6.4.4	Cell survival analysis using radiobiological models	191
6.4.4(a)	Linear quadratic (LQ) model	191
6.4.4(b)	Multi-target (MT) model.....	192
6.4.4(c)	Repairable conditionally repairable (RCR) model .	194

6.4.4(d)	Pade' linear quadratic (PLQ) model	195
6.4.4(e)	Two-component (2C) model.....	196
6.4.4(f)	Kavanagh and Newman (KN) model.....	197
6.4.5	Quantification of DEF, SER and RER	199
6.4.5(a)	Dose enhancement factor (DEF).....	199
6.4.5(b)	Sensitization enhancement ratio (SER)	201
6.4.5(c)	Radiation enhancement ratio (RER)	202
6.4.6	Reactive oxygen species (ROS)	204
6.4.6(a)	ROS measured with and without 1.9 nm of AuNPs.	204
6.4.6(b)	ROS comparison between different AuNPs sizes...	205
6.4.6(c)	Comparison between different beam types.....	206
6.4.7	Proton beam dose verification during samples irradiation	207
6.5	Discussion.....	209
6.5.1	Gold nanoparticles (AuNPs) cellular uptake in HCT 166 cells.....	209
6.5.2	Gold nanoparticles (AuNPs) localization for HCT 116 cells..	210
6.5.3	Cytotoxicity of the gold nanoparticles (AuNPs) to the HCT 116 cells.....	211
6.5.4	Cell survival analysis using radiobiological models	212
6.5.5	Quantification of DEF, SER and RER	215
6.5.6	Reactive Oxygen Species (ROS) Measurements	216
6.5.6(a)	ROS production with and without 1.9 nm of AuNPs.	216
6.5.6(b)	Effects of AuNPs sizes to ROS production	217
6.5.6(c)	Effects of beam types to ROS production.....	219

CHAPTER 7 PART III: ADVANCED RADIOTHERAPY; SYNCHROTRON MONOENERGETIC PHOTON BEAM THERAPY 222

7.1	Introduction.....	222
7.1.1	Synchrotron Radiation.....	222
7.1.2	Synchrotron kilovoltage monoenergetic photon beam.....	222
7.1.3	The exclusive characteristic of Synchrotron Light.....	224
7.1.4	Australian synchrotron	224
7.1.5	Synchrotron radiation applications.....	225
7.1.6	Synchrotron radiation properties and application.....	227
7.2	Literature Review	228
7.3	Materials and Methods	230
7.3.1	Mouse's Mastocytoma (P815) cell lines preparation	230
7.3.2	Gold nanoparticles (AuNPs) preparation	230
7.3.3	Cell survival study.....	230
7.3.4	Samples preparation for irradiation	231
7.3.4(a)	Cells samples preparation	231
7.3.4(b)	Irradiation Setup.....	231
7.3.4(c)	Radiation Dosimetry	232
7.3.5	Cell Survival Measurement	233
7.3.5(a)	Viability Assay.....	233
7.3.6	Data analysis.....	234
7.3.6(a)	Radiobiological modelling.....	234
7.3.6(b)	Methodology for quantifying radiosensitization effects of AuNPs.....	234
7.4	Results	235

7.4.1	Cell survival analysis using radiobiological models	235
7.4.1(a)	Linear quadratic (LQ) model	235
7.4.1(b)	Multi-target (MT) model.....	240
7.4.1(c)	Repairable conditionally repairable (RCR) model .	243
7.4.1(d)	Pade' linear quadratic (PLQ) model	247
7.4.1(e)	Two-component (2C) model.....	252
7.4.1(f)	Repair model (RM)	256
7.4.2	Comparison of cell survival analysis according to beam quality.....	261
7.4.3	Radiobiological parameters analysis	261
7.4.4	Quantification of DEF, SER, RER and REF	272
7.4.4(a)	Dose Enhancement Factor (DEF)	272
7.4.4(b)	Sensitization Enhancement Ratio (SER).	277
7.4.4(c)	Radiation Enhancement Ratio (RER)	282
7.4.4(d)	Radiation Enhancement Factor (REF)	287
7.4.5	Evaluation on the influence of beam energies and AuNPs sizes on the radiosensitization.	288
7.5	Discussion.....	294
7.5.1	Cell survival and radiobiological parameters analysis	294
7.5.2	Quantification of DEF, SER, RER and REF	297
7.5.3	Influence of beam energies and AuNPs sizes on the radiosensitization effects.	299
CHAPTER 8 CONCLUSION		301
8.1	Conventional beams radiotherapy	301
8.2	Proton beam therapy	306

8.3	Synchrotron monoenergetic photon beam therapy	307
8.4	Limitations	309
8.5	Future recommendations	309

REFERENCES	311
-------------------------	------------

APPENDICES

APPENDIX A	TURNITIN SCREENING REPORT
APPENDIX B	PUBLICATION LIST
APPENDIX C	CONFERENCE PRESENTATIONS
APPENDIX D	GOLD NANOPARTICLE SAMPLES

LIST OF TABLES

	Page
Table 2.1 The characteristic and properties of AuNPs	21
Table 3.1 Radiobiological model equations with the parameters that explained the intrinsic interactions.	53
Table 4.1 LQ model parameters for 6 MV photon beam irradiation with and without AuNPs.	68
Table 4.2 LQ model parameters for 10 MV photon beam irradiation with and without AuNPs.....	69
Table 4.3 LQ model parameters for 6 MeV electron beam irradiation with and without AuNPs.....	70
Table 4.4 LQ model parameters for 15 MeV electron beam irradiation with and without AuNPs.....	71
Table 4.5 LQ model parameters for brachytherapy irradiation with and without AuNPs.	72
Table 4.6 MT model parameters for 6 MV photon beam irradiation with and without AuNPs.	74
Table 4.7 MT model parameters for 10 MV photon beam irradiation with and without AuNPs.....	75
Table 4.8 MT model parameters for 6 MeV electron beam irradiation with and without AuNPs.....	76
Table 4.9 MT model parameters for 15 MeV electron beam irradiation with and without AuNPs.....	77
Table 4.10 MT model parameters for brachytherapy irradiation with and without AuNPs.	78
Table 4.11 RCR model parameters for 6 MV photon beam irradiation with and without AuNPs.....	80
Table 4.12 RCR model parameters for 10 MV photon beam irradiation with and without AuNPs.....	81
Table 4.13 RCR model parameters for 6 MeV electron beam irradiation with and without AuNPs.....	82
Table 4.14 RCR model parameters for 15 MeV electron beam irradiation with and without AuNPs.	83

Table 4.15	RCR model parameters for brachytherapy irradiation with and without AuNPs.	84
Table 4.16	PLQ model parameters for 6 MV photon beam irradiation with and without AuNPs.....	86
Table 4.17	PLQ model parameters for 10 MV photon beam irradiation with and without AuNPs.....	87
Table 4.18	PLQ model parameters for 6 MeV electron beam irradiation with and without AuNPs.....	88
Table 4.19	PLQ model parameters for 15 MeV electron beam irradiation with and without AuNPs.	89
Table 4.20	PLQ model parameters for brachytherapy irradiation with and without AuNPs.	90
Table 4.21	2C model parameters for 6 MV photon beam irradiation with and without AuNPs.	92
Table 4.22	2C model parameters for 10 MV photon beam irradiation with and without AuNPs.....	93
Table 4.23	2C model parameters for 15 MeV electron beam irradiation with and without AuNPs.....	94
Table 4.24	KN model parameters for 6 MeV electron beam irradiation with and without AuNPs.....	95
Table 4.25	KN model parameters for brachytherapy irradiation with and without AuNPs.	96
Table 4.26	Repair model parameters for 6 MV photon beam irradiation with and without AuNPs.....	98
Table 4.27	Repair model parameters for 10 MV photon beam irradiation with and without AuNPs.....	99
Table 4.28	Repair model parameters for 6 MeV electron beam irradiation with and without AuNPs.	100
Table 4.29	Repair model parameters for 15 MeV electron beam irradiation with and without AuNPs.	101
Table 4.30	Repair model parameters for brachytherapy irradiation with and without AuNPs.	102
Table 4.31	Linear quadratic model parameters for photon beam, electron beam and brachytherapy.....	111

Table 4.32	Multi-target model parameters for photon beam, electron beam and brachytherapy.	112
Table 4.33	Repairable conditionally repair model parameters for photon beam, electron beam and brachytherapy.	113
Table 4.34	Pade' linear quadratic model parameters for photon beam, electron beam and brachytherapy.	114
Table 4.35	Two-components model parameters for photon beam, electron beam and brachytherapy.	115
Table 4.36	Repair model parameters for photon beam, electron beam and brachytherapy.	116
Table 4.37	Kavanagh and Newman model parameters for photon beam, electron beam and brachytherapy.	117
Table 4.38	The dose enhancement factor (DEF) values for 6 MV photon beam from cell survival curves of different radiobiology models.	119
Table 4.39	The dose enhancement factor (DEF) values for 10 MV photon beam from cell survival curves of different radiobiology models.	120
Table 4.40	The dose enhancement factor (DEF) values for 6 MeV electron beam from cell survival curves of different radiobiology models.	121
Table 4.41	The dose enhancement factor (DEF) values for 15 MeV electron beam from cell survival curves of different radiobiology models.	122
Table 4.42	The dose enhancement factor (DEF) values for brachytherapy from cell survival curves of different radiobiology models. ...	123
Table 4.43	The sensitization enhancement ratio (SER) values for 6 MV from cell survival curves of different radiobiology models.	126
Table 4.44	The sensitization enhancement ratio (SER) values for 10 MV from cell survival curves of different radiobiology models. ...	127
Table 4.45	The sensitization enhancement ratio (SER) values for 6 MeV from cell survival curves of different radiobiology models. ...	128
Table 4.46	The sensitization enhancement ratio (SER) values for 15 MeV from cell survival curves of different radiobiology models. ...	129

Table 4.47	The sensitization enhancement ratio (SER) values for brachytherapy from cell survival curves of different radiobiology models.....	130
Table 4.48	The radiation enhancement ratio (RER) values for 6 MV photon beam from cell survival curves of different radiobiology models.....	132
Table 4.49	The radiation enhancement ratio (RER) values for 6 MV photon beam from cell survival curves of different radiobiology models.....	133
Table 4.50	The radiation enhancement ratio (RER) values for 6 MeV electron beam from cell survival curves of different radiobiology models.....	134
Table 4.51	The radiation enhancement ratio (RER) values for 15 MeV electron beam from cell survival curves of different radiobiology models.....	135
Table 4.52	The radiation enhancement ratio (RER) values for brachytherapy from cell survival curves of different radiobiology models. ...	136
Table 4.53	The radiation enhancement factor (REF) values for photon and electron beams from cell survival curves of multi-target models.....	137
Table 4.54	PLQ model parameter for irradiation with different sizes of AuNPs.....	139
Table 4.55	PLQ model parameter for irradiation with different concentration of AuNPs.	141
Table 4.56	PLQ model parameter for irradiation with different types of cells.	143
Table 4.57	Dose error for megavoltage photon beams radiotherapy	146
Table 4.58	Dose error for megavoltage electron beams radiotherapy.....	149
Table 4.59	Isodose verification error for brachytherapy irradiation	151
Table 6.1	LQ model parameters for 150 MeV proton beam irradiation with and without AuNPs.....	192
Table 6.2	MT model parameters for 150 MeV proton beam irradiation with and without AuNPs.....	193
Table 6.3	RCR model parameters for 150 MeV proton beam irradiation with and without AuNPs.	194

Table 6.4	PLQ model parameters for 150 MeV proton beam irradiation with and without AuNPs.....	195
Table 6.5	2C model parameters for 150 MeV proton beam irradiation with and without AuNPs.....	196
Table 6.6	KN model parameters for 150 MeV proton beam irradiation with and without AuNPs.....	197
Table 6.7	The dose enhancement factor (DEF) values for 150 MeV proton beam from cell survival curves of different radiobiology models.....	200
Table 6.8	The sensitization enhancement ratio (SER) values for 150 MeV proton beam from cell survival curves of different radiobiology models.....	202
Table 6.9	The radiation enhancement ratio (RER) values for 150 MeV proton beam from cell survival curves of different radiobiology models.....	203
Table 6.10	Values of proton beam dose verification.....	207
Table 7.1	The characteristic of synchrotron light.....	224
Table 7.2	LQ model parameters for 30 keV synchrotron irradiation with and without AuNPs.	236
Table 7.3	LQ model parameters for 40 keV irradiation with and without AuNPs.....	237
Table 7.4	LQ model parameters for 70 keV irradiation with and without AuNPs.....	238
Table 7.5	LQ model parameters for 81.5 keV irradiation with and without AuNPs.....	239
Table 7.6	MT model parameters for 30 keV irradiation with and without AuNPs.....	241
Table 7.7	MT model parameters for 40 keV irradiation with and without AuNPs.....	241
Table 7.8	MT model parameters for 81.5 keV irradiation with and without AuNPs.....	242
Table 7.9	RCR model parameters for 30 keV irradiation with and without AuNPs.....	244
Table 7.10	RCR model parameters for 40 keV irradiation with and without AuNPs.....	244

Table 7.11	RCR model parameters for 70 keV irradiation with and without AuNPs.....	245
Table 7.12	RCR model parameters for 81.5 keV irradiation with and without AuNPs.....	246
Table 7.13	PLQ model parameters for 30 keV irradiation with and without AuNPs.....	248
Table 7.14	PLQ model parameters for 40 keV irradiation with and without AuNPs.....	249
Table 7.15	PLQ model parameters for 70 keV irradiation with and without AuNPs.....	250
Table 7.16	PLQ model parameters for 81.5 keV irradiation with and without AuNPs.....	251
Table 7.17	2C model parameters for 30 keV irradiation with and without AuNPs.....	252
Table 7.18	2C model parameters for 40 keV irradiation with and without AuNPs.....	253
Table 7.19	2C model parameters for 70 keV irradiation with and without AuNPs.....	254
Table 7.20	2C model parameters for 81.5 keV irradiation with and without AuNPs.....	255
Table 7.21	RM model parameters for 30 keV irradiation with and without AuNPs.....	257
Table 7.22	RM model parameters for 40 keV irradiation with and without AuNPs.....	258
Table 7.23	RM model parameters for 70 keV irradiation with and without AuNPs.....	259
Table 7.24	RM model parameters for 81.5 keV irradiation with and without AuNPs.....	260
Table 7.25	Linear quadratic model parameters for synchrotron beam irradiations.....	266
Table 7.26	Multi target model parameters for synchrotron beam irradiations.	267
Table 7.27	Repairable conditionally repair model parameters for synchrotron beam irradiations.	268

Table 7.28	Pade' linear quadratic model parameters for synchrotron beam irradiations.....	269
Table 7.29	Two-components model parameters for synchrotron beam irradiations.....	270
Table 7.30	Repair model parameters for synchrotron beam irradiations. .	271
Table 7.31	The dose enhancement factor (DEF) values for 30 keV synchrotron beam from cell survival curves of different radiobiology models.	273
Table 7.32	The dose enhancement factor (DEF) values for 40 keV synchrotron beam from cell survival curves of different radiobiology models.	274
Table 7.33	The dose enhancement factor (DEF) values for 70 keV synchrotron beam from cell survival curves of different radiobiology models.	275
Table 7.34	The dose enhancement factor (DEF) values for 81.5 keV synchrotron beam from cell survival curves of different radiobiology models.	276
Table 7.35	The sensitization enhancement ratio (SER) values for 30 keV synchrotron from cell survival curves of different radiobiology models.....	278
Table 7.36	The sensitization enhancement ratio (SER) values for 40 keV synchrotron from cell survival curves of different radiobiology models.....	279
Table 7.37	The sensitization enhancement ratio (SER) values for 70 keV synchrotron from cell survival curves of different radiobiology models.....	280
Table 7.38	The sensitization enhancement ratio (SER) values for 81.5 keV synchrotron from cell survival curves of different radiobiology models.....	281
Table 7.39	The radiation enhancement ratio (RER) values for 30 keV synchrotron beam from cell survival curves of different radiobiology models.	283
Table 7.40	The radiation enhancement ratio (RER) values for 40 keV synchrotron beam from cell survival curves of different radiobiology models.	284
Table 7.41	The radiation enhancement ratio (RER) values for 70 keV synchrotron beam from cell survival curves of different radiobiology models.	285

Table 7.42	The radiation enhancement ratio (RER) values for 81.5 keV synchrotron beam from cell survival curves of different radiobiology models.	286
Table 7.43	The radiation enhancement factor (REF) values for 30 keV, 40 keV, 70 keV and 81.5 keV synchrotron beams from cell survival curves of multi-target model.	287

LIST OF FIGURES

	Page
Figure 1.1 The evolution of cancer radiotherapy treatments	2
Figure 1.2 The different levels of radiotherapy development. Reproduced from Joiner et al., 2009.....	3
Figure 1.3 The time-scale of effects of radiation interaction with biological materials.	6
Figure 1.4 DNA damages mechanism of single and double strand breaks. .	7
Figure 1.5 Survival curve of HeLa cells proliferation versus dose (Puck and Marcus, 1956).....	9
Figure 2.1 Nanomedicine in radiotherapy	19
Figure 2.2 Energy dependence of the theoretical of DEF for several Au aqueous mixtures (from bottom to top, the mass proportion of Au in water, w_{Au} range from 0.01 to 1.	24
Figure 3.1 The research summary.....	41
Figure 3.2 Cervical cancer (HeLa) cell lines	42
Figure 3.3 Human colon carcinoma (HCT 116) cell lines.....	43
Figure 3.4 Photon beam irradiation setup.	48
Figure 3.5 Electron beam irradiation setup.....	49
Figure 3.6 Brachytherapy irradiation setup.	50
Figure 3.7 The flow of the process of clonogenic assay for cell survival measurement.....	52
Figure 4.1 The uptake of AuNPs nanoparticles into HeLa cells as determined by an increase in granularity (SSC). Incubation with (a) no AuNPs (b) 1.9 nm AuNPs (c) 5 nm AuNPs (d) 15 nm AuNPs.....	61
Figure 4.2 AuNPs localization inside HeLa cells (100 μ m magnifications).	62
Figure 4.3 The percentage of the cell's viability at different AuNPs (1.9 nm) concentrations versus incubation time (24, 48 and 72 hours). The errors are a standard deviation from three independent experiments (mean $\pm$ SD, n=3).....	63

Figure 4.4	The percentage of the cell's viability versus different concentrations of 5 nm AuNPs at 24, 48 and 72 hours incubation time. The errors are a standard deviation from three independent experiments (mean $\pm$ SD, n=3).....	65
Figure 4.5	The percentage of the cell's viability versus different concentrations of 15 nm AuNPs at 24, 48 and 72 hours incubation time. The errors are a standard deviation from three independent experiments (mean $\pm$ SD, n=3).....	66
Figure 4.6	The cell survival curves for 6 MV photon beam irradiation with and without AuNPs fitted using the LQ model.	68
Figure 4.7	The cell survival curves for 10 MV photon beam irradiation with and without AuNPs fitted using the LQ model.	69
Figure 4.8	The cell survival curves for 6 MeV electron beam irradiation with and without AuNPs fitted using the LQ model.	70
Figure 4.9	The cell survival curves for 15 MeV electron beam irradiation with and without AuNPs fitted using the LQ model.	71
Figure 4.10	The cell survival curves for brachytherapy irradiation with and without AuNPs using the LQ model.	72
Figure 4.11	The cell survival curves for 6 MV photon beam irradiation with and without AuNPs fitted using the MT model.....	74
Figure 4.12	The cell survival curves for 10 MV photon beam irradiation with and without AuNPs fitted using the MT model.....	75
Figure 4.13	The cell survival curves for 6 MeV electron beam irradiation with and without AuNPs fitted using the MT model.....	76
Figure 4.14	The cell survival curves for 15 MeV electron beam irradiation with and without AuNPs fitted using the MT model.	77
Figure 4.15	The cell survival curves for brachytherapy irradiation with and without AuNPs using the MT model.....	78
Figure 4.16	The cell survival curves for 6 MV photon beam irradiation with and without AuNPs fitted using the RCR model.....	80
Figure 4.17	The cell survival curves for 10 MV photon beam irradiation with and without AuNPs fitted using the RCR model.....	81
Figure 4.18	The cell survival curves for 6 MeV electron beam irradiation with and without AuNPs fitted using RCR model.	82
Figure 4.19	The cell survival curves for 15 MeV electron beam irradiation with and without AuNPs fitted using RCR model.	83

Figure 4.20	The cell survival curves for brachytherapy irradiation with and without AuNPs fitted using RCR model.	84
Figure 4.21	The cell survival curves for 6 MV photon beam irradiation with and without AuNPs fitted using the PLQ model	86
Figure 4.22	The cell survival curves for 10 MV photon beam irradiation with and without AuNPs fitted using the PLQ model	87
Figure 4.23	The cell survival curves for 6 MeV electron beam irradiation with and without AuNPs fitted using the PLQ model	88
Figure 4.24	The cell survival curves for 15 MeV electron beam irradiation with and without AuNPs fitted using the PLQ model	89
Figure 4.25	The cell survival curves for brachytherapy irradiation with and without AuNPs fitted using PLQ model	90
Figure 4.26	The cell survival fraction curves for 6 MV photon beam irradiation with and without AuNPs fitted using the 2C model	92
Figure 4.27	The cell survival fraction curves for 10 MV photon beam irradiation with and without AuNPs fitted using the 2C model	93
Figure 4.28	The cell survival fraction curves for 15 MeV electron beam irradiation with and without AuNPs fitted using the 2C model	94
Figure 4.29	The cell survival fraction curves for 6 MeV electron beam irradiation with and without AuNPs fitted using the KN model	95
Figure 4.30	The cell survival fraction curves for brachytherapy irradiation with and without AuNPs fitted using the KN model	96
Figure 4.31	The cell survival curves for 6 MV photon beam irradiation with and without AuNPs fitted using the repair model	98
Figure 4.32	The cell survival curves for 10 MV photon beam irradiation with and without AuNPs fitted using repair model	99
Figure 4.33	The cell survival curves for 6 MeV electron beam irradiation with and without AuNPs fitted using the repair model	100
Figure 4.34	The cell survival curves for 15 MeV electron beam irradiation with and without AuNPs fitted using the repair model	101
Figure 4.35	The cell survival curves for brachytherapy irradiation with and without AuNPs fitted using the repair model	102

Figure 4.36	The survival curves for 6 MV photon beam according to different radiobiological models. Figure details with (a) LQ model, (b) MT model, (c) RCR model, (d) PLQ model, (e) RM model and (f) 2C model.....	104
Figure 4.37	The survival curves for 10 MV photon beam according to different radiobiological models. Figure details with (a) LQ model, (b) MT model, (c) RCR model, (d) PLQ model, (e) RM model and (f) 2C model.....	105
Figure 4.38	The survival curves for 6 MeV electron beam according to different radiobiological models. Figure details with (a) LQ model, (b) MT model, (c) RCR model, (d) PLQ model, (e) RM model and (f) KN model.....	106
Figure 4.39	The survival curves for 15 MeV electron beam according to different radiobiological models. Figure details with (a) LQ model, (b) MT model, (c) RCR model, (d) PLQ model, (e) RM model and (f) 2C model.....	107
Figure 4.40	The survival curves for brachytherapy according to different radiobiological models. Figure details with (a) LQ model, (b) MT model, (c) RCR model, (d) PLQ model, (e) RM model and (f) KN model.....	108
Figure 4.41	Dose enhancement factor (DEF) quantified for 6 MV photon beam from cell survival curves of different radiobiology models.....	119
Figure 4.42	Dose enhancement factor (DEF) quantified for 10 MV photon beam from cell survival curves of different radiobiology models.....	120
Figure 4.43	Dose enhancement factor (DEF) quantified for 6 MeV electron beam from cell survival curves of different radiobiology models.....	121
Figure 4.44	Dose enhancement factor (DEF) quantified for 15 MeV electron beam from cell survival curves of different radiobiology models.....	122
Figure 4.45	Dose enhancement factor (DEF) quantified for brachytherapy from cell survival curves of different radiobiology models. ...	123
Figure 4.46	Sensitization enhancement ratio (SER) quantified for 6 MV photon beam from cell survival curves of different radiobiology models.....	126

Figure 4.47	Sensitization enhancement ratio (SER) quantified for 10 MV photon beam from cell survival curves of different radiobiology models.....	127
Figure 4.48	Sensitization enhancement ratio (SER) quantified for 6 MeV electron beam from cell survival curves of different radiobiology models.....	128
Figure 4.49	Sensitization enhancement ratio (SER) quantified for 15 MeV photon beam from cell survival curves of different radiobiology models.....	129
Figure 4.50	Sensitization enhancement ratio (SER) quantified for brachytherapy from cell survival curves of different radiobiology models.....	130
Figure 4.51	Radiation enhancement ratio (RER) quantified for 6 MV photon beam from cell survival curves of different radiobiology models.....	132
Figure 4.52	Radiation enhancement ratio (RER) quantified for 10 MV photon beam from cell survival curves of different radiobiology models.....	133
Figure 4.53	Radiation enhancement ratio (RER) quantified for 6 MeV electron beam from cell survival curves of different radiobiology models.....	134
Figure 4.54	Radiation enhancement ratio (RER) quantified for 15 MeV electron beam from cell survival curves of different radiobiology models.....	135
Figure 4.55	Radiation enhancement ratio (RER) quantified for brachytherapy from cell survival curves of different radiobiology models. ...	136
Figure 4.56	Radiation enhancement factor (REF) quantified for photon and electron beams from cell survival curves of multi-target models.....	137
Figure 4.57	The cells survival curves for 1.9, 5 and 15 nm AuNPs under brachytherapy irradiation.....	139
Figure 4.58.	The cells survival curves for 1, 2 and 3 nm AuNPs under brachytherapy irradiation.....	141
Figure 4.59	The cells survival curves for HeLa and HCT116 cells under brachytherapy irradiation.....	142
Figure 4.60	Calibration curve for 6 MV photon beam	144

Figure 4.61	Prescribed dose versus measured dose for 6 MV photon beam	144
Figure 4.62	Calibration curve for 10 MV photon beam	145
Figure 4.63	Prescribed dose versus measured dose for 10 MV photon beam	145
Figure 4.64	Calibration curve for 6 MeV electron beam.....	147
Figure 4.65	Prescribed dose versus measured dose for 6 MeV electron beam.	147
Figure 4.66	Calibration curve for 15 MeV electron beam.....	148
Figure 4.67	Prescribed dose versus measured dose for 15 MeV electron beam.	148
Figure 4.68	Isodose distribution for brachytherapy irradiation of 1 Gy.	150
Figure 4.69	Isodose distribution for brachytherapy irradiation of 2 Gy	150
Figure 4.70	Isodose distribution for brachytherapy irradiation of 4 Gy	151
Figure 6.1	Depth dose distribution of proton spread-out bragg peak and other types of radiotherapy beams	178
Figure 6.2	The schematic diagram of the experimental set-up of cell irradiation with proton beams.....	185
Figure 6.3	The experimental set-up of cell's proton beam irradiation.	185
Figure 6.4	The uptake of AuNPs nanoparticles into HCT 116 cells (a) without AuNPs and (b) with 1.9 nm AuNPs.	189
Figure 6.5	AuNPs localization inside HCT 116 cells (100 magnifications).	189
Figure 6.6	The 1.9 nm AuNPs cytotoxicity on HCT 116 cell.	190
Figure 6.7	The cell survival curves for 150 MeV proton beam irradiation with and without AuNPs fitted using LQ model.	191
Figure 6.8	The cell survival curves for 150 MeV proton beam irradiation with and without AuNPs fitted using MT model.	192
Figure 6.9	The cell survival curves for 150 MeV proton beam irradiation with and without AuNPs fitted using RCR model.	194
Figure 6.10	The cell survival curves for 150 MeV proton beam irradiation with and without AuNPs fitted using PLQ model.....	195

Figure 6.11	The cell survival curves for 150 MeV proton beam irradiation with and without AuNPs fitted using 2C model.....	196
Figure 6.12	The cell survival curves for 150 MeV proton beam irradiation with and without AuNPs fitted using KN model.....	197
Figure 6.13	The survival curves for 150 MeV proton beam according to different radiobiological models. This figure details with (a) LQ model, (b) MT model, (c) RCR model, (d) PLQ model, (e) KN model and (f) 2C model.....	198
Figure 6.14	Dose enhancement factor (DEF) quantified for 150 MeV proton beam from cell survival curves of different radiobiology model.	199
Figure 6.15	Sensitization enhancement ratio (SER) quantified for 150 MeV proton beam from cell survival curves of different radiobiology models.....	201
Figure 6.16	Radiation enhancement ratio (RER) quantified for 150 MeV proton beam from cell survival curves of different radiobiology models.....	203
Figure 6.17	The percentage of ROS production with and without 1.9 nm AuNPs after irradiation with 150 MeV proton beam at 2 Gy radiation dose.....	204
Figure 6.18	The percentage of ROS generation induced by 1.9 nm, 5 nm, and 15 nm AuNPs after irradiation with 150 MeV proton beam. ...	205
Figure 6.19	The comparison of ROS generation induced by 1.9 nm, 5 nm, and 15 nm AuNPs after irradiation with 150 MeV proton beam, 6 MV, 10 MV photon beam and 0.38 MeV gamma ray.	206
Figure 6.20	Measured dose versus prescribed dose for proton beam irradiation.	208
Figure 7.1	Synchrotron work-flow and components of beam production.....	223
Figure 7.2	Australian Synchrotron, Image obtained from Google map satellite (10/9/2019).....	225
Figure 7.3	Australian Synchrotron research fields.	225
Figure 7.4	Setup of cell irradiation with Australian Synchrotron beam radiotherapy.....	231
Figure 7.5	Dosimetry setup for Synchrotron beam irradiation. Cell in PCR tubes were located in front of Gafchromic EBT3 film.....	232

Figure 7.6	The cell survival curves for 30 keV synchrotron irradiation with and without AuNPs fitted using the LQ model.	236
Figure 7.7	The cell survival curves for 40 keV irradiation with and without AuNPs fitted using the LQ model.	237
Figure 7.8	The cell survival curves for 70 keV irradiation with and without AuNPs fitted using the LQ model.	238
Figure 7.9	The cell survival curves for 81.5 keV irradiation with and without AuNPs fitted using the LQ model.	239
Figure 7.10	The cell survival fraction curves for 30 keV irradiation with and without AuNPs using MT model.....	240
Figure 7.11	The cell survival fraction curves for 40 keV irradiation with and without AuNPs using MT model.....	241
Figure 7.12	The cell survival fraction curves for 81.5 keV irradiation with and without AuNPs using MT model.....	242
Figure 7.13	The cell survival fraction curves for 30 keV irradiation with and without AuNPs using RCR model.....	243
Figure 7.14	The cell survival fraction curves for 40 keV irradiation with and without AuNPs using RCR model.....	244
Figure 7.15	The cell survival fraction curves for 70 keV irradiation with and without AuNPs, using RCR model.....	245
Figure 7.16	The cell survival fraction curves for 81.5 keV irradiation with and without AuNPs using RCR model.....	246
Figure 7.17	The cell survival fraction curves for 30 keV irradiation with and without AuNPs fitted using PLQ model.....	248
Figure 7.18	The cell survival fraction curves for 40 keV irradiation with and without AuNPs fitted using PLQ model.....	249
Figure 7.19	The cell survival fraction curves for 70 keV irradiation with and without AuNPs fitted using PLQ model.....	250
Figure 7.20	The cell survival fraction curves for 81.5 keV irradiation with and without AuNPs, fitted using PLQ model.....	251
Figure 7.21	The cell survival fraction curves for 30 keV irradiation with and without AuNPs, fitted using the 2C model.....	252
Figure 7.22	The cell survival fraction curves for 40 keV irradiation with and without AuNPs, fitted using the 2C model.....	253

Figure 7.23	The cell survival fraction curves for 70 keV irradiation with and without AuNPs, fitted using the 2C model.....	254
Figure 7.24	The cell survival fraction curves for 81.5 keV irradiation with and without AuNPs, fitted using the 2C model.....	255
Figure 7.25	The cell survival fraction curves for 30 keV irradiation with and without AuNPs, fitted using the RM model.	257
Figure 7.26	The cell survival fraction curves for 40 keV irradiation with and without AuNPs, fitted using the RM model.	258
Figure 7.27	The cell survival fraction curves for 70 keV irradiation with and without AuNPs, fitted using the RM model.	259
Figure 7.28	The cell survival fraction curves for 81.5 keV irradiation with and without AuNPs, fitted using the RM model.	260
Figure 7.29	The survival curves for 30 keV synchrotron beam according to different radiobiological models. Figure details with (a) LQ model, (b) MT model, (c) RCR model, (d) PLQ model, (e) RM model and (f) 2C model.....	262
Figure 7.30	The survival curves for 40 keV synchrotron beam according to different radiobiological models. Figure details with (a) LQ model, (b) MT model, (c) RCR model, (d) PLQ model, (e) 2C model and (f) RM model.	263
Figure 7.31	The survival curves for 70 keV synchrotron beam according to different radiobiological models. Figure details with (a) LQ model, (b) RCR model, (c) PLQ model, (d) RM model, (e) 2C model.	264
Figure 7.32	The survival curves for 81.5 keV synchrotron beam according to different radiobiological models. Figure details with (a) LQ model, (b) MT model, (c) RCR model, (d) PLQ model, (e) RM model and (f) 2C model.....	265
Figure 7.33	Dose enhancement factor (DEF) quantified for 30 keV synchrotron beam from cell survival curves of different radiobiology models.	273
Figure 7.34	Dose enhancement factor (DEF) quantified for 40 keV synchrotron beam from cell survival curves of different radiobiology models.	274
Figure 7.35	Dose enhancement factor (DEF) quantified for 70 keV synchrotron beam from cell survival curves of different radiobiology models.	275

Figure 7.36	Dose enhancement factor (DEF) quantified for 81.5 keV synchrotron beam from cell survival curves of different radiobiology models.	276
Figure 7.37	Sensitization enhancement ratio (SER) quantified for 30 keV synchrotron beam from cell survival curves of different radiobiology models.	278
Figure 7.38	Sensitization enhancement ratio (SER) quantified for 40 keV synchrotron beam from cell survival curves of different radiobiology models.	279
Figure 7.39	Sensitization enhancement ratio (SER) quantified for 70 keV synchrotron beam from cell survival curves of different radiobiology models.	280
Figure 7.40	Sensitization enhancement ratio (SER) quantified for 81.5 keV synchrotron beam from cell survival curves of different radiobiology models.	281
Figure 7.41	Radiation enhancement ratio (RER) quantified for 30 keV synchrotron beam from cell survival curves of different radiobiology models.	282
Figure 7.42	Radiation enhancement ratio (RER) quantified for 40 keV synchrotron beam from cell survival curves of different radiobiology models.	283
Figure 7.43	Radiation enhancement ratio (RER) quantified for 70 keV synchrotron beam from cell survival curves of different radiobiology models.	284
Figure 7.44	Radiation enhancement ratio (RER) quantified for 81.5 keV synchrotron beam from cell survival curves of different radiobiology models.	285
Figure 7.45	Radiation enhancement factor (REF) quantified for 30 keV, 40 keV, 70 keV and 81.5 keV synchrotron beams from cell survival curves of multi-target model.	287
Figure 7.46	The ratio of cells viability for control and treated cells with ..	289
Figure 7.47	The ratio of cells viability for control and treated cells with ..	289
Figure 7.48	The ratio of cells viability for control and treated cells with ..	290
Figure 7.49	The ratio of cells viability for control and treated cells with ..	290
Figure 7.50	The ratio of cells viability for control and treated cells with ..	291
Figure 7.51	The ratio of cells viability for control and treated cells with ..	291

Figure 7.52	The ratio of cells viability for control and treated cells with ..	292
Figure 7.53	Combination of bar and line graph showing comparison of experimental and theoretical DEF.	293
Figure 8.1	Final results summary.....	308

LIST OF ABBREVIATIONS

^{125}I	Iodine-125
^{192}Ir	Iridium-192
^{198}Au	Gold-198
2C	2-Components
Au	Gold
AuNPs	Gold nanoparticles
CO ₂	Carbon dioxide
DEF	Dose Enhancement Factor
DMEM	Dulbecco's Modified Eagle's medium
DNA	Deoxyribonucleic acid
D-PBS	Dulbecco's Phosphate-Buffered Saline
DSB	Double strand breaks
EBT2	External beam therapy 2
EDTA	Ethylenedinitrilotetraacetic acid
EPR	Enhanced permeability and retention effect
FBS	Fetal bovine serum
HDR	High dose rate
IGRT	Image guided radiotherapy
IMRT	Intensity-modulated radiotherapy
KN	Kavanagh-Newman
LINAC	Linear accelerator
LET	Linear energy transfer

LQ	Linear Quadratic
MT	Multi-target
NPs	Nanoparticles
NTCP	Normal tissue complication probability
PLQ	Pade' Linear Quadratic
TCP	Tumor control probability
SER	Sensitisation enhancement ratio
RCR	Repairable Conditionally Repairable
REF	Radiation Enhancement Factor
RER	Radiation Enhancement Ratio
RM	Repair Model
SSD	Source to skin distance
SSB	Single strand breaks

LIST OF SYMBOLS

a	The initial mean number of damage events per unit dose
α	The direct killing of cell “single hit” (linear component)
α_1	The slope of a single-hit component
α_n	The slope of a compound multi-hit component
b	The maximum amount of damage that can be repaired
β	The impact of cell killing from “double hits” (quadratic component)
c	The loss of repair due to more complex damage
cm^2	Centimeter square
D	Dose
D_1	Dose at initial slope
D_q	The size of the shoulder of the curve
D_0	Dose at final slope
Gy	Gray
g/mol	Gram per mol
kV	Kilovoltage
K_0	Linear rate
K_{OG}	Exponential rate
M	Mega
MeV	Megavoltage
mg/ml	Miligram per mililiter
mM	Milimol
Mol	Mol
Molar	Molarity

MU/min	Monitor Unit per Minutes
MV	Mega voltage
n	Number of targets / hit number
μl	Microliter
γ	The quantity lethal lesions

**PEMODELAN RADIOBIOLOGI BAGI KESAN RADIOSENSITIVITI
PARTIKEL NANO EMAS DALAM TEKNIK KONVENSIONAL DAN
RADIOTERAPI TERMAJU**

ABSTRAK

Keberkesanan strategi teknik radioterapi dengan nanoteknologi menjanjikan penyelesaian dalam mengatasi permasalahan yang timbul dalam perawatan radioterapi konvensional seperti kelemahan dalam memberi kesan radiasi secara selektif dan bersasar terhadap tumor yang bersifat kalis radiasi. Partikel nano emas telah menjadi bahan kajian yang pesat untuk bertindak sebagai penggalak kesan radiosensitiviti dalam perawatan klinikal radioterapi. Meskipun terdapat banyak kajian yang telah dijalankan, kepesatan penggunaan partikel nano emas sebagai pemeka sinaran memerlukan pendekatan kajian yang sistematik dan mendalam untuk menilai secara menyeluruh kesan radiobiologi terhadap rawatan radioterapi. Dalam penyelidikan ini, kesan radiosensitiviti telah dikaji menggunakan pelbagai parameter eksperimen terhadap rawatan radioterapi klinikal menggunakan tenaga radiasi yang berbeza megavolt antaranya alur foton, elektron dan juga dos tinggi brakiterapi (bahan Iridium-192). Selain radioterapi konvensional, penggunaan rawatan radioterapi termaju seperti alur proton dan kilovolt monoenergi foton 'synchrotron radiation' turut dikaji. Analisa yang mendalam dengan menggunakan model-model radiobiologi dan cara-cara mengkuantifikasinya juga turut diteliti secara spesifik. Pengaruh kesan radiosensitiviti oleh partikel nano emas dari segi saiz, kepekatan dan jenis sel yang dirawat, beserta pengkajian yang meliputi internalisasi, lokalisasi dan kesan toksiknya terhadap sel turut di dikaji secara terperinci. Kebolehgunaan partikel nano emas untuk rawatan

radioterapi konvensional terbukti menghasilkan kesan radiosensitiviti terutamanya dengan dos tinggi brakiterapi, di mana ianya menunjukkan kesan lebih baik berbanding radioterapi alur elektron dan foton. Impak radiosensitiviti yang berkesan terbukti lebih besar dengan perawatan alur proton dan kilovolt monoenergi foton ‘synchrotron radiation’ yang bersepadanan dengan ramalan teori. Pengesahan melalui model-model radiobiologi bertujuan untuk menghuraikan lekukan kemandirian sel bergantung kepada jenis kualiti alur radiasi beserta cara-cara mengkuantifikasinya. Berserta dengan itu, setiap model radiobiologi berserta parameter tersendiri turut berperanan menjadi petunjuk yang menerangkan mekanisme kejadian yang disebabkan oleh kesan radiosensitiviti. Saiz dan kepekatan partikel nano emas turut mempengaruhi kesan radiosensitiviti, bergantung juga pada perbezaan jenis sel yang dikaji. Sebelum melakukan kajian kesan radiosensitiviti radioterapi, penggunaan partikel nano emas yang optima turut diambil kira dari segi kepekatan yang tidak toksik dan intenalisasinya terhadap sel. Kesimpulannya, keberkesanan radiosensitiviti partikel nano emas boleh dicapai dengan menggunakan radioterapi klinikal megavot, brakiterapi dan juga radioterapi termaju seperti terapi alur proton dan ‘synchrotron’ monoenergi foton radioterapi. Pemilihan secara terperinci model-model radiobiologi, mampu memberi pemahaman tentang kesan radiobiologi sel yang teraruh dari partikel nano emas dan juga piawaian cara-cara mengkuantifikasi amat penting untuk memastikan kesesuaian parameter yang terbaik bagi rawatan klinikal partikel nano emas. Cadangan yang jelas dan tertumpu amat penting dalam pengumpulan data praklinikal bagi mempercepatkan peralihan kegunaan partikel nano emas ke peringkat aplikasi klinikal kepada pesakit.

RADIOBIOLOGICAL MODELLING OF GOLD NANOPARTICLES
RADIOSENSITIZATION EFFECTS IN CONVENTIONAL AND
ADVANCED RADIOTHERAPY TECHNIQUES

ABSTRACT

Improvement of radiotherapy techniques with nanotechnology is a promising strategy to overcome the limitations arises in conventional treatment such as lack of eradication selectivity and radioresistance characteristic of targeted tumour. Gold nanoparticles (AuNPs) is a subject of growing interest to induce radiosensitization effects with potential application in clinical radiotherapy. Despite numerous evidences, development and application of AuNPs as radiosensitizer require systematic and comprehensive experimental approaches to fully evaluate the radiobiological impact in radiotherapy. In this study, multiparametric investigations on the radiosensitization effects were conducted using different energies of clinical megavoltage photon, electron, and high-dose rate (HDR) gamma rays from Ir-192 source. In addition to conventional radiotherapy, advanced techniques using proton beam and monoenergetic synchrotron photon beam of kilovoltage energies were also employed. Comprehensive analysis using different radiobiological models and quantification methods were specifically examined. Influence of AuNPs size, concentration and types of cells on the radiosensitization effects were also elucidated including internalization, localization and cytotoxicity of AuNPs. Applicability of AuNPs for clinical conventional radiotherapy have been proven where radiosensitization effects have been observed especially for HDR brachytherapy that show better effects compare to electron and photon beam therapies. Substantially bigger impact of AuNPs radiosensitization have been confirmed for proton beam and

monoenergetic kilovoltage synchrotron photon beam in concurrently with theoretical prediction. Validity of radiobiological models to describe the cell survival curve is dependent on the beam quality as well as quantification methods. Radiobiological models and their parameters also could be adopted as indicator to explain the mechanistic events in the AuNPs' radiosensitization effects. The AuNPs size and concentration are found to influence the radiosensitization effects and different types of cells exhibit different radiosensitivity responses. The radiosensitization impacts of AuNPs with radiotherapy beams were considered with prior indication on the cellular internalization of AuNPs and the non-toxic concentration for optimal AuNPs application. As conclusion, effective radiosensitization by AuNPs could be achieved for megavoltage clinical radiotherapy, brachytherapy and advanced radiotherapy such as proton beam therapy and monoenergetic synchrotron beam radiotherapy. Precise radiobiological characterization drawn from radiobiological models may provide insight towards radiobiological impacts induced by AuNPs and standardization of quantification methods is crucial for highlighting suitable parameters for AuNPs clinical application. Clear directive recommendation from comprehensive preclinical data provided in this study may expedite the clinical translation of AuNPs for human application.

CHAPTER 1

INTRODUCTION

1.1 Modern radiotherapy in cancer treatment

Millions of people globally are dying with life-threatening cancer diseases for decades. However, radiation therapy (RT) leads in cancer treatment by delivering higher tumour doses while preserving healthy tissues aims for organ preservation, an abiding principle of radiotherapy, thus resulting in increasing cancer cures with the least morbidity. Radiotherapy aims to encompass all cancer cells with sufficient therapeutic doses of radiation that aim on inhibition of cancer cells proliferating capacity, eliminate the malignant cells, reduce the risk of recurrence while simultaneously sparing surrounding normal tissues and ultimately to improve survival.

Enormous progress has been made on the development of precision RT treatments using linear accelerators that pave towards current advanced technologies. All efforts in understanding RT limitations and improved its ability to treat tumours have been done through extensive research and development. Advances in technologies specialized in radiation devices to improve RT such as dynamic multi-leaf collimators, automated treatment planning, new imaging modalities, powerful software operations and various treatment delivery methods help to achieve the conformal radiation dose.

The improvement of radiotherapy techniques is routing through several approaches. Firstly, the standard of prescribed dose and delivery at the target cancer region were elevated. Secondly, introduction of the new method beyond the conventional radiation techniques such as volumetric modulated arc therapy (VMAT) and particles beam therapy. Thirdly, the combination of image-guidance and radiotherapy enable dose monitoring delivery at daily treatment. Last and most

innovative outlook are exploring the radiobiological initiatives by manipulating the nature of cancer cells behavior to become more radiosensitive towards the radiation imposed (Joiner et al., 2009).

Figure 1.1 shows the evolution of the radiotherapy technique from standard conventional treatment to conformal radiotherapy and currently the emerging of particles beam therapy. A preclinical study on the synchrotron-based treatment is currently undergoing and could be available for patients in the near future.




Figure 1.1 The evolution of cancer radiotherapy treatments

1.2 Radiobiology in radiotherapy

The theoretical and experimental radiobiology in radiotherapy offer strategies and techniques from the most basic conventional therapy to specific treatment directly on the manipulating radiobiological cellular environment. There are three different levels on radiotherapy development as shown in Figure 1.2.




Figure 1.2 The different levels of radiotherapy development. Reproduced from Joiner et al., 2009.

1.2.1 Radiation induced cellular damage

Ionizing radiation causes atomic excitation and ionization of electron from the molecules of cells that will induce biological damages and cell death. This effect occurs in three phases which the physical phase, chemical phase and biological phase as described in the following section.

1.2.1(a) The time scale of radiation effects

1.2.1(a)(i) Physical phase

This phase portrays the mechanisms between charged particles and the atoms within the tissue composition. The light speed of electron takes about 10^{-18} second to pass over the DNA strands and about 10^{-14} second to go across a mammalian cell. The mechanism occurs when the external particles hit the orbital electrons resulting some of the electron from atoms being expelled (ionization) and elevating others to higher energy levels within an atom or molecule (excitation). The secondary electrons with sufficient energies may excite or ionize other atoms near their path. For example, 1 Gy of absorbed radiation dose will cause in excess of 10^5 ionizations within the volume of every cell in diameter of 10 μm .

1.2.1(a)(ii) Chemical phase

The chemical phase illustrates the process of atoms and molecules impaired recurred with other cellular components in accelerated chemical interactions. The formation of broken chemical bonds results from the processes of ionization and excitation direct to the production of 'free radicals'. These are highly potent with the characteristics which were a highly reactive need to the restoration of electronic charge equilibrium, which is accomplished within approximately 1 millisecond of radiation exposure. The important characteristic of the chemical phase is the competition between scavenging reactions, for example with sulphydryl compounds that

inactivated the free radicals and fixation reactions that lead to stable chemical changes in biologically important molecules.

1.2.1(a)(iii) Biological Phase

The end stage of biological phase determines all the subsequent processes of cell death. DNA lesions induced by radiation caused base damage, single-strand breaks (SSBs) and double-strand breaks (DSBs) are aforesaid to be most lethal. In the case of SSBs damage, precision removal damaged base carried out by glycosylases, forming damaged base or an abasic sites, which leads to fork collapse and DSB formation.

DSBs are identified by specific protein regulator that works for cell apoptosis responses or cell cycle arrest, thus stopping the proliferation of tumour cells with damaged DNA and inhibiting tumorigenesis. The time-scale of the observable effects of ionizing radiation may thus extend up to many years after exposure (Begg, Stewart & Vens, 2011). Figure 1.3 shows the time-scale of effects of radiation interaction with biological materials.




Figure 1.3 The time-scale of effects of radiation interaction with biological materials.

1.2.1(b) DNA damage mechanism

Clusters of energy deposition events (ionization and excitations) occur at the track of secondary electrons resulting in multiple closely-spaced lesions (multiply damaged sites) within a range of 20 nm. This process has been recognized as important for cell killing and in regard to the ability of cells to repair such lesions.

Irradiation generates damage in various patterns of lesions in DNA molecules such as strand rupture either single or double strand breaks, base alteration, sugars destruction and cross-links involving nuclear proteins such as histones and non-histones form of dimers. Altogether the number of DNA lesions produced by irradiation is about 100 distinct patterns. Alteration induced in the DNA of a cell by a dose of 1-2 Gy is approximately: modified base by the formation of radical

hydroperoxide > 1000; single strand breaks (SSB) ~1000; double-strand breaks (DSB) ~40 (Wouters & Begg, 2009).

The indirect effect of strand break plays a prevalent role in cell killing, the most frequent DNA lesion for in vitro study with the highest radiochemical yield. Single-strand break (SSB) produced a large portion of hydroperoxide radicals. Following breakage of the phosphodiester bond, the two strands separate.

Other experimental data show that low dose radiation produced early radiosensitivity DSB, which is a critical indicator for cell killing. While for higher doses, cell deaths are a consequence of unrepaired or mis-repaired DSB. Tremendous effect is observed with high LET irradiation, resulting in the formation of complex DSB lesions. Figure 1.4 shows the DNA damages mechanism of single and double strand break.




Figure 1.4 DNA damages mechanism of single and double strand breaks.

1.2.2 Radiation cell survival and damage

The success of radiotherapy depends on the ability to cause damage to the tumour's cells. Quantification of the damage can be done by using the different biological technique. However, clonogenic assay and cell survival curves are the basis for understanding radiation cell survival and damages.

1.2.2(a) Cell survival curves

The first cell survival curve used for quantitative evaluation of radiobiological was practised by Puck and Markus, 1956. Then in 2006, Nicolaas *et al.* had published the protocol for clonogenic assay as the assessment for in-vitro techniques, based on the ability of the cell considered to be survived then gives rise to a colony formation. The colonies containing more than 50 cells were counted and depicted in graphically by cell survival curve (Tubiana et al., 1990). Radiation sensitivity evaluation using this protocol of different adherent cell type had become the gold standard for radiation doses response.

The outcome of colonies formation will be presented in the so-called survival curve, which is consists of survival fraction versus dose. The common pattern shows the proportion of surviving cells (S_f) decreases as the dose (D) increases. The curve was plotted in semi-logarithmic coordinates ($\log S_f$ as a function of D). This type of plot emphasizes very small values of S at high doses but may sometimes less appreciate survival after low doses. Thus, it is crucial to manipulate curves response by presenting in mathematical functions. These are based on the hypothetical mechanisms of cell lethality or acute damages, which are always emphasized by radiobiological modelling (Tubiana et al., 1990). Figure 1.5 shows the survival curve of HeLa cells proliferation versus dose (Puck and Marcus, 1956). The survival curve

for single cells of the HeLa cells line depicted the formation of the shoulder of the curve is unequivocal and constitutes evidence for a multiple hit killing mechanism.




Figure 1.5 Survival curve of HeLa cells proliferation versus dose (Puck and Marcus, 1956).

1.3 Radiobiological model

Radiobiological modelling is used for quantitative radiation biology that will explain both dose-response and time-dose relationships.

1.3.1 Application of the LQ model

Radiobiological models primarily LQ model has been implemented over more than a decade in clinical radiotherapy. The quantitative mathematical model has been adequately simulated the shape of cell-survival curves for mammalian cells and was applied to assess the optimum clinical outcome from conventional therapy to sophisticated therapeutic approaches.

LQ model has been classified as the most common fitted radiobiological model to the survival dose curve. The LQ model describes the relationship between total isoeffective dose and the dose per fraction in fractionated radiotherapy. This model

forms the robust quantitative environment for considering the balance between acute and late reactions (and effect on the tumour) as dose per fraction and total dose changed. This is one of the most important developments in radiobiology application to radiotherapy. In the present time, it is strongly recommended that LQ model should always be used, with correctly chosen α/β ratio, to describe isoeffect dose relationships at least over the range of doses per fraction between 1 and 5 Gy. The α/β ratio describes the shape of the fractionation response: a low (0.5-6 Gy) is usually characteristic of late-responding normal tissues and indicates a rapid increase of total dose, with decreasing dose per fraction and a survival curve for the putative target cells that are significantly curved. While for high ratio (7-20 Gy) represents the condition of the early-responding normal tissues and rapidly-proliferating carcinomas; it indicates a less curved cell-survival response for putative target cells. The LQ model is an appropriate way to be used in clinical calculations and comparisons or in the change in total dose for an altered dose per fraction either old or new treatments. For late reactions, it is usually unnecessary to modify total dose in response to a change in overall time, but for early reactions (and for tumour response) a correction for overall treatment time should be included. Although the effect of time on biological effect is complex, the simple linear correction has been shown to be of some values.

1.3.1(a) The validity of the LQ model

The question regarding the validity of the LQ approach can only be addressed on an endpoint-by-endpoint basis. The LQ model has been applied to datasets from quite a few clinical studies, and there has in many cases been good agreement between the predicted and observed study outcome. This gives some confidence in using the model to estimate the effects of changed dose fractionation in a situation where there are clinical parameter estimates.

Data has supported that the implementation of the LQ model is reliable for dose or dose per fraction ranges from about 1 Gy to 5 Gy. However, as the dose range of the radiotherapy widens, the classical LQ model becomes less and less accurate (Brahme, 2011). According to Andisheh, et al., (2013) LQ model is not suitable in the high-dose region where it underestimates the surviving fraction in the high dose range. Its parameters are essential but to describe the more complex treatment, a realistic model is more desirable. Limitation of the LQ model in clinical radiotherapy could be listed as follow:

1. LQ model does not accurately explain the observed (in-vivo) clinical data
2. LQ model was derived largely from in-vitro study and does neglect the side effect irradiation on the neighbouring normal tissues.
3. LQ model does not consider the effect towards radioresistant cells which is also known as cancer stem cells response. (Kirkpatrick et al. 2008).

1.4 Problem statement and rationale of the study

Ideally, the behavior shown by AuNPs as biocompatible radiosensitizer had been proven by many studies. The highly productive of photoelectric interaction between AuNPs and x-ray especially at kilovoltage energy caused simultaneously increasing of secondary radiation beneficial to induce cell death significantly. However, the nature of kilovoltage x-ray beam was very strongly attenuated by soft tissues in which treatment limited only for superficial tumours. Therefore, megavoltage radiation used in clinical radiotherapy will be more promising as it has superior penetration that allows for greater dose uniformity and reduced the dose delivered to surrounding healthy tissues. The application of AuNPs with megavoltage radiotherapy could produce radiosensitization or dose enhancement as better as kilovoltage x-ray beam (McMahon et al. 2011, Liu et al., 2018). Radiosensitization effects have also been explored for advanced radiotherapy modalities using proton and synchrotron-based therapy (Cho et al., 2016, Enferadi et al., 2017). However, the data reported are still limited and identification on further parameters for quantifying AuNPs radiosensitization effects is extremely important for clinical stage.

Therefore, the novelty of this study is to determine the radiosensitization effects by AuNPs for different radiotherapy modalities: megavoltage photon beam, electron beam and high-dose rate (HDR) gamma rays from Ir-192 source available in HUSM (conventional radiotherapy). For advanced radiotherapy, we had advanced to investigate proton beam and monoenergetic synchrotron photon beam of kilovoltage energies from our international research collaboration team. The radiosensitization response is simultaneously manifested with various radiobiological model and quantification methods. Such efforts had never been done from other researchers in full detail, thus the results obtained from this thesis will contribute to a more

comprehensive data in unravelling the mechanisms that influence the tissue's radiobiological response and cells' reaction systems treated with AuNPs as radiosensitizer across multiple radiotherapy beams. This is extremely important when considering the wide range of various radiotherapy beams combined with AuNPs treatments; as such huge data range will encompass a great understanding of the complexity and specificity of identifying the ideal treatment selection and formulation when optimizing the radiation dose given for clinical translations.

1.5 General objective

To characterize the radiosensitization effects by gold nanoparticles (AuNPs) for advanced radiotherapy using multiple radiobiological models.

1.6 Specific objectives

1. To investigate the cytotoxicity, cellular uptake and intercellular localization of AuNPs.
2. To quantify the radiosensitization effects by AuNPs for photon beam, electron beam and HDR brachytherapy as well as proton beam and monoenergetic synchrotron beam.
3. To analyze the validity of different radiobiological models and quantification methods in characterizing the radiosensitization effects by AuNPs.
4. To evaluate parameters that influence the radiosensitization effects by AuNPs such as cell types, beam energy, nanoparticles size and concentration.

1.7 Thesis outlines

The thesis is divided into two parts. Part 1 is the study on conventional clinical radiotherapy which as follow photon beam, electron beam and HDR brachytherapy. The study was conducted at Hospital Universiti Sains Malaysia, Health Campus, Kubang Kerian, Kelantan.

Part II consists of the study conducted using specialized beam of the proton beam and monochromatic synchrotron photon beam. The study on proton beam was conducted at Hyogo Ion Beam Medical Center in Hyogo, Japan from the period of 2016-2018. The study using monochromatic synchrotron beam was conducted at Australian Synchrotron in Clayton Melbourne Australia in which the beam time was acquired in December 2015.

The chapters of the thesis:

Chapter 1: The introduction describes the modern radiotherapy approaches, the specification on radiobiological effects and the innovation of nanomedicine applications. The objectives of study are also emphasized.

Chapter 2: The literature review of the study details on gold nanoparticles application with radiotherapy, the mechanism of the interactions and the pre-clinical test of previous study.

Chapter 3: The methodology of the study was initially specified on cell culture maintenance, gold nanoparticles preparation, cellular localization, uptake and cytotoxicity assay protocol. The cell irradiations setup, radiation dosimetry and clonogenic assay were illustrated. Radiobiological models applied for cell survival curve and quantification methods of radiosensitization effects were then described.

Chapter 4: The description of the results begins with gold nanoparticles uptake, localization and cytotoxicity. The cell survival analysis using different radiobiological models were then presented. Linear Quadratic (LQ), Multi-Target (MT), Repairable Conditionally Repair (RCR), Pade' Linear Quadratic (PLQ), Repair (RM), Kavanagh and Newman (KN) and Two Components (2C) Models are validated. The survival curve of different beam was compared and analysed. Radiosensitization impact were quantified using different methods (DEF, SER, RER, REF). The radiosensitization effects due to AuNPs size, concentration and cell types are also examined.

Chapter 5: The findings of gold nanoparticles uptake, localization and cytotoxicity was discussed. The detailed-on the radiosensitization impact for conventional radiotherapy are explained. The influence of AuNPs sizes, concentrations and different cells response were justified.

Chapter 6: Introduction and literature on proton beam therapy was briefly described. The cell survival experimental work for proton beam was illustrated. The study was also supported by additional measurement of reactive oxygen species (ROS) due to AuNPs interaction with proton beam. All those findings were discussed in detail accordingly.

Chapter 7: A brief introduction on synchrotron radiation production and its applications is described. Literature review on previous challenge in overcome dose limitation and optimization in radiotherapy were also discussed. In this study, the experimental methods were explained, and results were analyzed using similar radiobiological models approaches. The quantification of radiosensitization effects has

also been evaluated. The experimental data were also supported by theoretical dose enhancement calculation. All the corresponding results were discussed.

Chapter 8: The conclusion of the study was reported by each main chapter, respectively. Limitations and future recommendations were also discussed briefly.

CHAPTER 2

LITERATURE REVIEW

2.1 Nanomedicine in radiotherapy

Nanomedicine is an active research area that holds great future to intercede with cancer treatment at the molecular level and deliver effective doses to targeted cancer cells with improved selectivity and lessened toxicities towards neighbour normal tissues. The core of nanomedicine is the development of nanoparticles, materials that hold unique distinctions such as nanoscale size, high surface-to-volume ratio and suitable physicochemical characteristics. Nanoparticles have wide range of types are able to act as a multifunctional agent that incorporates with the specific binding of drugs to targets in cancer cells or the tumour microenvironment, simultaneous visualization of tumours using innovative imaging techniques, prolonged drug-circulation times, controlled drug-release kinetics, and superior dose scheduling for improved patient compliance. In an example, the carbon nanotubes have future usefulness in cancer thermal ablation therapy, because of their electrical and thermal conductivity. However, their properties such as length and diameter might cause inflammatory and toxic effects (Markman et al., 2013).

Novel metal nanoparticles in particular gold nanoparticles are also capable as a therapeutic agent, imaging contrast media and nanocarrier of such proteins, DNA or RNA. The gold core is considered to be non-toxic and the therapeutic payload can be forced to be released from the conjugate due to their photo-physical properties (Webster et al., 2013). In radiotherapy, nanoparticles possess properties as a radiosensitizer to enhance radiation dose to the target by increasing the probability of radiation interaction and production of the secondary electron that will cause DNA damage. Examples of nanoparticles based radiosensitizer that has the potential to be

applied in radiotherapy are metallic nanoparticles (Au, Bi, Pt, Gd), superparamagnetic iron oxide nanoparticles, quantum dots and various hybrid nanoparticles.

Metallic nanoparticles composite a packed of metal particles which are functionalized as scatter medium when interact with high energy radiation (megavoltage) to produce secondary radiation. The secondary radiation directly localized into tumours cells in large amount at a short distance. This mechanism gives therapeutic radiation in tumours area at the same time despair neighbour of healthy tissues. The concept of using high Z materials incorporated in cells was initially investigated using iodine which presented higher efficiency for secondary radiation production (Matsudaira et al., 1980). This study was also supported by a separate study using gold films that indicated multifold and significant dose enhancement effect upon irradiation (Regulla et al., 1998). Dose enhancement effects induced by high Z materials are believed to be more efficient by resizing the gold or others types of metal into nanoparticles.

Several types of metallic nanoparticles have been introduced as radiosensitizer show similar significant dose enhancement effects when tested both *in-vitro* and *in-vivo*. Metallic nanoparticles such as gadolinium, iron oxide, titanium and silver nanoparticles provide similar outcome of dose enhancement or radiosensitization effects (Tokumitsu et al., 2000; Xu et al., 2009; Khoei et al., 2014, Nakayama et al., 2016). Superparamagnetic iron oxide nanoparticles for examples withhold special properties of highly biocompatible while collaterally induced cytotoxic effects when interact with radiation (Klein et al., 2013). In some cases, these nanoparticles are also combined with chemotherapeutic agents or nanocomposite metal based like (Fe₂O₄/Ag) for increased efficiency (Huang et al., 2012) (Zhao et al., 2012).

Other than metal-based nanoparticles, the non-metal nanoparticles also exhibit potential to acts as radiosensitizer. Klein et al. (2012) have investigated the ultrasmall uncapped and aminosilanized oxidized silicon nanoparticles to treat breast cancer cells with X-rays. Quantum dots which made of semiconductor (CaF, LaF, ZnS or ZnO) have been developed as photosensitizer capable in producing radicals upon absorption of visible light. This type of light however gives less penetration and suitable specifically for superficial cancer treatments (Shao et al., 2011).

Nanomedicine in general occupied various applications in radiotherapy. Summary most of all classification of nanomedicine applied in elevating radiation efficiency is presented in Figure 1.6.




Figure 2.1 Nanomedicine in radiotherapy

2.2 Application of Gold Nanoparticles (AuNPs) in radiotherapy

The development of potential high Z materials as radiosensitizers in recent years becomes more interesting. The basic principle of primary radiation collide with high Z elements deposited secondary radiation locally surrounding targeted cancer area may improve radiotherapy efficiency in treating malignant diseases. Pioneer studies have proven the presence of iodine in mammalian cells in culture indeed induced radiosensitization or dose enhancement effects that enhance cell killing when combined with radiation. Subsequent studies with other types high Z matters had been reported such as gold (Au), silver (Ag), hafnium oxide, platinum (Pt), gadolinium, iron oxide (Fe_3O_4) and quantum dots (QDs). The most promising high Z elements which is gold, tuned into nanoparticles scale given efficiency distribution throughout the specific target. Gold nanoparticles (AuNPs) features of synthetic versatility, capable for size, shape and surface characteristics modification.

Regulla et al. (2000) were first verified the dose enhancement effects using monolayer culture of C3H/10T1/2 mouse embryo fibroblasts irradiated with 48 keV X-ray on gold foil. This is followed by seminal work by Hainfeld et al. (2010) on nano-small sized 1.9 nm AuNPs that were injected into the mice bearing SCCV11 squamous cell carcinomas. The results show improvement in the survival days by the increment from 53 days (-gold) to 76 days (+gold). The promising results of AuNPs are due to the higher mass attenuation coefficient of AuNPs in which at 100 keV of photon energy, gold could provide 2.7 times better sensitivity per unit weight than iodine and gadolinium. This indication picturized the existence of AuNPs in the targeted tumour may cause the dose enhancement effects in radiotherapy (Goswami et al., 2017). Improvised gold nanoparticles i.e: AuNP-dual peptide has been investigated to show that at 4 Gy, dose enhancement factor (DEF) up to 3.2 had been produced (Nicol et al.,

2017). AuNPs in combination with radiation also delayed the tumour growth around 10.2 days instead of 3.4 day with irradiation alone (Nicol et al., 2018).

Other promising study using multifunction AuNPs-formulation (Chitosan-capped-AuNPs-Doxorubicin) with MCF-7 cells irradiated using 6 MV photon beam exhibited potent radiosensitization effects up to 2 fold compared to irradiation only (Fathy et al. 2018). Another latest investigation reported that 20 nm of AuNPs-PEG-anti-human epidermal growth factor receptor type 2 (HER2) antibody showed a significant dose enhancement at only 3 Gy of radiation dose (Hatoyama et al., 2019). Shreds of evidence clearly portrayed the potential of the AuNPs application as radiosensitizer on top of others different promising usage of AuNPs in many areas.

2.2.1 Characteristic and properties of AuNPs

Gold nanoparticles have been reported to show potential as radiosensitizers for radiotherapy. This mainly due to its special characteristic and properties in Table 2.1.

Table 2.1 The characteristic and properties of AuNPs

Characteristics	✓ High-Z atomic number ($Z=79$), an ideal material for radiosensitization reactions when combining with radiotherapy (Hainfeld & Slatkin, 2008). ✓ Gold being very inert, it is highly biocompatible which issues need to be considered as in vivo inflammatory effect would be resulted (Shukla et al., 2005). ✓ Nanoparticles surface ratio able to enhance the effect of the radiation over a large area of tumour thus eliminating the need of the nanoparticles to be delivered to all the cells of the tumour tissues (Jain et al., 2007).
-----------------	---

Properties	✓ Nanoparticles are known to have low systemic clearance as compared to low molecular contrast agents such as iodine allowing the photosensitizing material enough time to get absorbed into the tumour tissue (Longmire et al., 2008). ✓ Nanoparticles are known to be well absorbed into the systemic circulation, better permeation into the tumour tissue. This along with lower clearance rate results in the enhanced permeation and retention (EPR) effect (Iyer et al., 2006). ✓ Better attaching target with antibodies or other targeting moieties, given a good specifically delivered to the tumour cells location (Hainfeld et al., 2008). ✓ The feasible nano shape based on delivery requirements of the tumours tissues (such as its size and location) so as to achieve optimum delivery and effects (Chithrani et al., 2010). ✓ Improving specific tissue pharmacokinetics, cause them easy to image and quantify by using optimum dose level for best result (Xia et al., 2016).
------------	---

2.2.2 Radiosensitization Effects by AuNPs

2.2.2(a) Theoretical dose enhancement by high Z materials

A non-Monte Carlo method also known as a systematic analysis of mass attenuation coefficient in different energies of photon had been simulated by Corde et al. (2004) for dose enhancement produced by iodine. This theoretical model-based calculation was also been used by Rahman et al. (2009) on AuNPs. The theoretically expected dose enhancement ratio or factor was calculated from the variation of the mass energy-absorption coefficient of the target due to the presence of high Z matter such as AuNPs. The dose enhancement factor (DEF) calculation is shown in the Equation 2.1:

$$DEF = \frac{\left(\frac{\mu_{en}}{\rho}\right)_E^{water+Au}}{\left(\frac{\mu_{en}}{\rho}\right)_E^{water}} = \frac{w_{Au}\left(\frac{\mu_{en}}{\rho}\right)_E^{Au} + (1-w_{Au})\left(\frac{\mu_{en}}{\rho}\right)_E^{water}}{\left(\frac{\mu_{en}}{\rho}\right)_E^{water}} \quad (2.1)$$

The mass-energy absorption coefficient for the considered compound were simulated with monochromatic x-rays beam (energy: E) and in the fraction by weight of Au in the mixture. Figure 2.1 shows the theoretical DEF for several Au aqueous mixtures.




Figure 2.2 Energy dependence of the theoretical of DEF for several Au aqueous mixtures (from bottom to top, the mass proportion of Au in water, w_{Au} range from 0.01 to 1.